Highlights Ikena Oncology, Inc.

Equities

IKNA

US45175G1085

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
1.65 ^USD	-5.71%		-4.07%	-16.24%

29/05	HC Wainwright Adjusts Price Target on Ikena Oncology to $4 From $11, Maintains Buy Rating	MT
29/05	Wedbush Downgrades Ikena Oncology to Neutral From Outperform After Discontinuation of Lead Program IK-930, Adjusts PT to $2 From $8	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ikena Oncology to Cut Jobs, Explore Options, End IK-930 Program; Shares Rise After Hours	29/05	MT
Ikena Oncology, Inc. Announces Discontinue Development of IK-930	29/05	CI
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
North American Morning Briefing : Inflation Data -2-	12/03	DJ
Ikena Oncology, Inc. Provides Corporate Updates	19/01	CI
Ikena Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Ikena Oncology, Inc. Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial	09/11	CI
Ikena Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Ikena Oncology Shares Fall After Pionyr Immunotherapeutics Acquisition Completed	08/23/08	MT
Ikena Oncology Completes Acquisition of Pionyr Immunotherapeutics in All-Stock Deal	07/23/07	MT
Ikena Oncology, Inc. acquired Pionyr Immunotherapeutics Inc..	04/23/04	CI
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Ikena Oncology, Inc. Announces Preclinical Data in the Novel Investigational Hippo Pathway Inhibitor, Ik-930	17/23/17	CI
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Ikena Oncology Presents Preclinical Data on Ik-595, Best-In-Class Next-Generation Mek-Raf Complex Inhibitor, in Plenary Session At Aacr Special Conference on Ras Targeting	07/23/07	CI
Ikena Oncology Gets FDA Fast Track Label for IK-175 Plus Nivolumab to Treat Urothelial Carcinoma	06/23/06	MT
Ikena Oncology, Inc. Receives FDA Fast Track Designation for Novel Ahr Antagonist Ik-175 in Combination with Nivolumab to Treat Urothelial Carcinoma	06/23/06	CI
Ikena Oncology, Inc. Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update	28/22/28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ikena Oncology, Inc.

Equities

IKNA

US45175G1085

Highlights

Filters